SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Nuvelo (Nasdaq: NUVO)
An SI Board Since August 1997
Posts SubjectMarks Bans Symbol
286 28 0 NUVO
Emcee:  CharlieS Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
261Nuvelo Announces Strategic Focus and Reports Fourth Quarter and Year End 2002 ReSemiBull-2/24/2003
260Hyseq bought Variagenic's cash at a discount and increased their odds of surSr K-2/6/2003
259<i>I thought HYSQ took over VGNX but the article you posted talks about meSemiBull-2/6/2003
258I'm a bit confused. I thought HYSQ took over VGNX but the article you postesteve kammerer-2/4/2003
257Hyseq and VARIAGENICS Merge to Form New Company, Nuvelo Monday February 3, 6:30SemiBull-2/3/2003
256Hyseq To Mull Reverse Stock Split For Nasdaq Compliance Wednesday January 29, 5SemiBull-1/30/2003
255Variagenics Rebuffs Acacia Offer; Backs Hyseq Merger Tuesday January 21, 11:17 SemiBull-1/21/2003
254Hyseq and VARIAGENICS Advancing Toward Completion of Merger Thursday December 1SemiBull-12/19/2002
253Hyseq to buy Variagenics for about $56 mln Monday November 11, 7:09 am ET SUNSemiBull-11/11/2002
252Hyseq And VARIAGENICS Announce Merger Monday November 11, 6:53 am ET SUNNYVALSemiBull-11/11/2002
251Hyseq Pharmaceuticals Announces Third Quarter 2002 Financial Results Thursday OSemiBull-10/24/2002
250SurroMed and Callida Genomics Sign Agreement with the National Institute of StanSemiBull-10/1/2002
249Hyseq Pharmaceuticals and UCSF Sign License Agreement with Celera Diagnostics SemiBull-9/9/2002
248Hyseq Pharmaceuticals Announces Second Quarter Financial Results SUNNYVALE, CalSemiBull-7/25/2002
247Hyseq Pharmaceuticals Initiates Phase I Trial for Lead Product Candidate AlfimepSemiBull-7/1/2002
246Biotech Royalty's Tarnished Crown forbes.comSemiBull-6/25/2002
245Hyseq Pharmaceuticals Appoints Nina Giles to Lead Business Development Efforts SemiBull-6/24/2002
244Hyseq Pharmaceuticals Appoints Two New Members to Its Board Of Directors SUNNYVSemiBull-6/17/2002
243Hyseq Pharmaceuticals, Inc. to Be Featured at BIO 2002 Business Forum SUNNYVALESemiBull-6/9/2002
242Agilent Technologies and Callida Genomics Sign Licensing Agreement for DNA MicroSemiBull-5/20/2002
241Hyseq Pharmaceuticals Takes Steps to Further Strengthen Its Biopharmaceutical FoSemiBull-5/14/2002
240Hyseq Pharmaceuticals Announces First Quarter Financial Results SUNNYVALE, CaliSemiBull-4/25/2002
239Hyseq Pharmaceuticals, Inc. Announces $15 Million Private Placement SUNNYVALE, SemiBull-4/9/2002
238Hyseq Pharmaceuticals to Present at the BIO CEO & Investor Conference On FebSemiBull-2/14/2002
237Genetastix Announces Research Collaboration With Hyseq SANTA CLARA, Calif., FebSemiBull-2/13/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News